You do realise that the m6a RNA epitranscriptomic proteins (like FTO) control the transcription of CD49 type proteins. Below is one example including Integrin alpha 6, a CD49 type protein. I'm sure there are other papers. It is only because the m6a RNA epitranscriptomic science is currently developing that there is not a clearer understanding of how m6A RNA proteins modify and control the trascription of CD49 as well as other proteins.
1
https://www.thelancet.com/article/S2352-3964(19)30510-9/pdf
@AlCp Please, read the journal article that I linked you. Here is the strategic implications section. If you disagree with me, feel free to contact the author of the paper. Their analysis is where I draw my conclusions.
@AlCp Also, you should familiarise yourself with precision oncology - using specific biomarkers to select the appropriate therapy. Precision oncology is by far the largest area of oncology, which RAC fit neatly within.
@Wasabibarako I'm free to comment on any stock. Just because my comments are critical and contrary to the mean does not make them invalid or unwarranted. Healthy criticism is beneficial for any discussion. Also, if people on this forum continue to comment incorrectly on a stock and science that I know very well, then I'm free to provide some insight. I've spent a long time studying this, and wouldn't want misinformation spreading to more people.
@fattchoi
1. The IMU shareprice has dropped around 2.5x more percentage wise than RAC in that time. Hence, by your logic, the IMU SP was more sensitive to Daniel's HC ban than RAC.
2. Herceptin is one that comes to mind, with USD $3.732B in sales for 2020 (a). I would take sales over safety or tolerability any day. Also, I have seen no updated safety or tolerability data for HERvaxx. Although, it's not like it really matters, as the HERvaxx sample size is too small to show any significant benefit or failure for safety and there are multiple publications like this one that state Herceptin is safe and tolerable in patients (b). Over 2500 patients were evaluated in that study.
a
https://www.roche.com/dam/jcr:1f38a5ed-8881-43da-aa1f-ff922b40069e/en/210421_IR_Roche_Q1_en.pdf
b
https://pubmed.ncbi.nlm.nih.gov/28625777/
3. With respect, you are blinded by your own bias.
4. Because the FTO inhibitory mechanism of action was only discovered in 2020, and there are now 29 different cancers linked to its expression and the inhibition/knockdown sensitizes cancer cells to 16 different therapies and counting. If you don't know the stock or science, do not comment. Simple.
